Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06576635 · ClinicalTrials.gov registry record · NA

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

A NA study of NSCLC, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
NA
Development phase
29
Enrollment target
1
Study location

NCT06576635 is a NA study of NSCLC that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 29 participants, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06576635, a NA study of NSCLC, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
NA
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs.

Conditions Studied

Interventions

  • DRUG Docetaxel
  • DRUG Pemetrexed
  • DRUG Paclitaxel
  • DRUG Gemcitabine
  • DRUG Vinorelbine

Study Locations (1)

Illinois

  • University of Illinois Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2024-12-16
Est. Completion 2026-09
Phase NA

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT06576635

The ClinicalTrials.gov registry entry for NCT06576635 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (87% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.

NCT06576635 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06576635 about?

NCT06576635 is a clinical study titled "LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients". This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA ...

What is the current status of trial NCT06576635?

This trial is currently recruiting. It is a NA study. The enrollment target is 29 participants. The study started on 2024-12-16. Estimated completion is 2026-09.

What conditions does trial NCT06576635 study?

This clinical trial studies the following conditions: NSCLC.

What interventions are being tested in trial NCT06576635?

The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), Vinorelbine (DRUG).

Who is sponsoring clinical trial NCT06576635?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06576635 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.